<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630444</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002687</org_study_id>
    <nct_id>NCT04630444</nct_id>
  </id_info>
  <brief_title>Riluzole Effects on Hippocampus Biomarkers</brief_title>
  <official_title>An Investigational Study of Riluzole Effects on Hippocampus Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain &amp; Behavior Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the clinical efficacy of the anti-glutamatergic medication riluzole in&#xD;
      posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our&#xD;
      laboratory previously has identified using MRS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Actual">March 16, 2019</completion_date>
  <primary_completion_date type="Actual">March 16, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing the clinical efficacy of riluzole in PTSD</measure>
    <time_frame>weeks 1-8</time_frame>
    <description>Testing the hypothesis that riluzole monotherapy will yield within-subject reductions in PTSD total symptoms (CAPS total score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing the clinical efficacy of riluzole in PTSD</measure>
    <time_frame>weeks 1-8</time_frame>
    <description>Testing the hypothesis that riluzole monotherapy will yield within-subject reductions in PTSD intrusion symptoms (CAPS intrusion subscale)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 PTSD patients receiving riluzole 100 mg daily (50 mg bid).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>30 PTSD patients with riluzole 100 mg daily (50 mg bid).</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female age 18-65.&#xD;
&#xD;
          2. Right handed&#xD;
&#xD;
          3. Able to provide written informed consent.&#xD;
&#xD;
          4. Meets DSM-5 criteria for PTSD (current month and past 3 months).&#xD;
&#xD;
          5. If already receiving psychiatric intervention(s), must be on a stable regimen.&#xD;
&#xD;
          6. Has normal physical examination, laboratory test results, and electrocardiogram&#xD;
             results at pre-treatment visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwillingness or inability to provide written informed consent.&#xD;
&#xD;
          2. Unable to swallow pills.&#xD;
&#xD;
          3. Unable to tolerate blood draws.&#xD;
&#xD;
          4. Currently enrolled in another intervention study.&#xD;
&#xD;
          5. Imminent risk for self-harm (assessed by a licensed clinician)&#xD;
&#xD;
          6. Active psychotic symptoms.&#xD;
&#xD;
          7. Current panic disorder.&#xD;
&#xD;
          8. Lifetime history of schizophrenia spectrum disorder, bipolar disorder, obsessive&#xD;
             compulsive disorder, anorexia nervosa, seizure disorder, or neurologic disorder.&#xD;
&#xD;
          9. Urine toxicology positive for drug(s) of abuse.&#xD;
&#xD;
         10. Evidence of any clinically significant medical disease.&#xD;
&#xD;
         11. Women who test positive for ÃŸ-HCG, self-report as pregnant, or are nursing.&#xD;
&#xD;
         12. Substance or alcohol abuse within 3 months of Visit 1. Substance or alcohol dependence&#xD;
             within 6 months of Visit 1.&#xD;
&#xD;
         13. Excessive caffeine use, defined as regular consumption of &gt;700mg caffeine per day.&#xD;
&#xD;
         14. Treatment with an antipsychotic, valproate, other anticonvulsant, reversible MAOI&#xD;
             within 4 weeks of Visit 1. Other excluded medications will be those with (1) known&#xD;
             glutamatergic effects, (2) previous MRS evidence of effects on brain glutamate, (3)&#xD;
             potential effects on riluzole levels or (4) risk of neutropenia - used within 4 weeks&#xD;
             of the first study visit.&#xD;
&#xD;
         15. Previous exposure to riluzole or ketamine.&#xD;
&#xD;
         16. Treatment with any investigational medicine within 30 days of Visit 1.&#xD;
&#xD;
         17. Treatment with electroconvulsive therapy (ECT) within 3 months of Visit 1.&#xD;
&#xD;
         18. Uncorrected thyroid disease.&#xD;
&#xD;
         19. Any screening laboratory assay that is deemed to be a clinically significant&#xD;
             abnormality by the investigator, with the exception of liver function tests (AST, ALT,&#xD;
             alkaline phosphatase), which must be within 1.5 times the upper limit of normal.&#xD;
&#xD;
         20. Any contraindications to having an MRI scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Isabelle Rosso</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

